Nctid:
NCT06612840
Payload:
{"hasResults"=>false, "derivedSection"=>{"miscInfoModule"=>{"versionHolder"=>"2024-10-04"}, "conditionBrowseModule"=>{"meshes"=>[{"id"=>"D000008175", "term"=>"Lung Neoplasms"}, {"id"=>"D000002289", "term"=>"Carcinoma, Non-Small-Cell Lung"}], "ancestors"=>[{"id"=>"D000012142", "term"=>"Respiratory Tract Neoplasms"}, {"id"=>"D000013899", "term"=>"Thoracic Neoplasms"}, {"id"=>"D000009371", "term"=>"Neoplasms by Site"}, {"id"=>"D000009369", "term"=>"Neoplasms"}, {"id"=>"D000008171", "term"=>"Lung Diseases"}, {"id"=>"D000012140", "term"=>"Respiratory Tract Diseases"}, {"id"=>"D000002283", "term"=>"Carcinoma, Bronchogenic"}, {"id"=>"D000001984", "term"=>"Bronchial Neoplasms"}], "browseLeaves"=>[{"id"=>"M11172", "name"=>"Lung Neoplasms", "asFound"=>"Lung Cancer", "relevance"=>"HIGH"}, {"id"=>"M5546", "name"=>"Carcinoma, Non-Small-Cell Lung", "asFound"=>"Non-small Cell Lung Cancer", "relevance"=>"HIGH"}, {"id"=>"M5534", "name"=>"Carcinoma", "relevance"=>"LOW"}, {"id"=>"M14979", "name"=>"Respiratory Tract Neoplasms", "relevance"=>"LOW"}, {"id"=>"M16658", "name"=>"Thoracic Neoplasms", "relevance"=>"LOW"}, {"id"=>"M11168", "name"=>"Lung Diseases", "relevance"=>"LOW"}, {"id"=>"M14977", "name"=>"Respiratory Tract Diseases", "relevance"=>"LOW"}, {"id"=>"M5540", "name"=>"Carcinoma, Bronchogenic", "relevance"=>"LOW"}, {"id"=>"M5260", "name"=>"Bronchial Neoplasms", "relevance"=>"LOW"}], "browseBranches"=>[{"name"=>"Neoplasms", "abbrev"=>"BC04"}, {"name"=>"Respiratory Tract (Lung and Bronchial) Diseases", "abbrev"=>"BC08"}, {"name"=>"All Conditions", "abbrev"=>"All"}]}, "interventionBrowseModule"=>{"browseLeaves"=>[{"id"=>"M4225", "name"=>"Antibodies", "relevance"=>"LOW"}, {"id"=>"M10184", "name"=>"Immunoglobulins", "relevance"=>"LOW"}], "browseBranches"=>[{"name"=>"All Drugs and Chemicals", "abbrev"=>"All"}]}}, "protocolSection"=>{"designModule"=>{"phases"=>["PHASE1"], "studyType"=>"INTERVENTIONAL", "designInfo"=>{"allocation"=>"NA", "maskingInfo"=>{"masking"=>"NONE"}, "primaryPurpose"=>"TREATMENT", "interventionModel"=>"SINGLE_GROUP"}, "enrollmentInfo"=>{"type"=>"ESTIMATED", "count"=>20}}, "statusModule"=>{"overallStatus"=>"NOT_YET_RECRUITING", "startDateStruct"=>{"date"=>"2024-10", "type"=>"ESTIMATED"}, "expandedAccessInfo"=>{"hasExpandedAccess"=>false}, "statusVerifiedDate"=>"2024-09", "completionDateStruct"=>{"date"=>"2026-10", "type"=>"ESTIMATED"}, "lastUpdateSubmitDate"=>"2024-09-23", "studyFirstSubmitDate"=>"2024-09-23", "studyFirstSubmitQcDate"=>"2024-09-23", "lastUpdatePostDateStruct"=>{"date"=>"2024-09-25", "type"=>"ACTUAL"}, "studyFirstPostDateStruct"=>{"date"=>"2024-09-25", "type"=>"ACTUAL"}, "primaryCompletionDateStruct"=>{"date"=>"2026-10", "type"=>"ESTIMATED"}}, "outcomesModule"=>{"primaryOutcomes"=>[{"measure"=>"Phase Ia: Dose limiting toxicity (DLT)", "timeFrame"=>"Up to 21 days after the first dose", "description"=>"DLTs are assessed according to NCI-CTCAE v5.0 during the first cycle and defined as occurrence of any of the toxicities in DLT definition if judged by the investigator to be possibly, probably or definitely related to study drug administration."}, {"measure"=>"Phase Ia: Maximum tolerated dose (MTD)", "timeFrame"=>"Up to 21 days after the first dose", "description"=>"MTD is defined as the highest dose level at which no more than 1 in 6 participants experienced a DLT during the first cycle ."}, {"measure"=>"Phase Ia: Treatment-Emergent Adverse Event (TEAE)", "timeFrame"=>"Up to approximately 24 months", "description"=>"TEAE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally emerging, or any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition during the treatment of GNC-077 . The type, frequency and severity of TEAE will be evaluated during the treatment of GNC-077."}, {"measure"=>"Phase Ib: Recommended Phase II Dose (RP2D)", "timeFrame"=>"Up to approximately 24 months", "description"=>"The RP2D is defined as the dose level chosen by the sponsor (in consultation with the investigators) for phase II study, based on safety, tolerability, efficacy, PK, and PD data collected during the dose escalation study of GNC-077."}], "secondaryOutcomes"=>[{"measure"=>"Cmax", "timeFrame"=>"Up to approximately 24 months", "description"=>"Maximum serum concentration (Cmax) of GNC-077 will be investigated."}, {"measure"=>"Tmax", "timeFrame"=>"Up to approximately 24 months", "description"=>"Time to maximum serum concentration (Tmax) of GNC-077 will be investigated."}, {"measure"=>"AUC0-inf", "timeFrame"=>"Up to approximately 24 months", "description"=>"AUC0-inf is defined as area under the concentration-time curve from 0 to inf."}, {"measure"=>"AUC0-t", "timeFrame"=>"Up to approximately 24 months", "description"=>"AUC0-t is defined as area under the serum concentration-time curve from time 0 to the time of the last measurable concentration."}, {"measure"=>"CL (Clearance)", "timeFrame"=>"Up to approximately 24 months", "description"=>"CL in the serum of GNC-077 per unit of time will be investigated."}, {"measure"=>"T1/2", "timeFrame"=>"Up to approximately 24 months", "description"=>"Half-life (T1/2) of GNC-077 will be investigated."}, {"measure"=>"ADA (anti-drug antibody)", "timeFrame"=>"Up to approximately 24 months", "description"=>"Frequency of anti-GNC-077 antibody (ADA) will be investigated."}, {"measure"=>"Objective Response Rate (ORR)", "timeFrame"=>"Up to approximately 24 months", "description"=>"ORR is defined as the percentage of participants, who has a CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions). The percentage of participants who experiences a confirmed CR or PR is according to RECIST 1.1."}, {"measure"=>"Disease Control Rate (DCR)", "timeFrame"=>"Up to approximately 24 months", "description"=>"The DCR is defined as the percentage of participants who has a CR, PR, or Stable Disease (SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease \\[PD: at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD\\])."}, {"measure"=>"Duration of Response (DOR)", "timeFrame"=>"Up to approximately 24 months", "description"=>"The DOR for a responder is defined as the time from the participant's initial objective response to the first date of either disease progression or death, whichever occurs first."}, {"measure"=>"Progression-free survival (PFS)", "timeFrame"=>"Up to approximately 24 months", "description"=>"The PFS is defined as the time from the participant's first dose of GNC-077 to the first date of either disease progression or death, whichever occurs first."}, {"measure"=>"Overall survival (OS)", "timeFrame"=>"Up to approximately 24 months", "description"=>"Overall survival (OS) is defined as the time between the subject's randomization date and subject's death."}]}, "oversightModule"=>{"oversightHasDmc"=>false, "isFdaRegulatedDrug"=>false, "isFdaRegulatedDevice"=>false}, "conditionsModule"=>{"conditions"=>["Non-small Cell Lung Cancer", "Solid Tumor"]}, "descriptionModule"=>{"briefSummary"=>"This study is an open-label, multicenter, dose-escalation and cohort expansion phase I clinical study to evaluate the safety, tolerability, pharmacokinetics characteristics or preliminary efficacy and antitumor activity in patients with Locally advanced or metastatic non-small cell lung cancer and other solid tumors."}, "eligibilityModule"=>{"sex"=>"ALL", "stdAges"=>["ADULT", "OLDER_ADULT"], "minimumAge"=>"18 years", "healthyVolunteers"=>false, "eligibilityCriteria"=>"Inclusion Criteria:\n\n1. Able to understand the informed consent form, voluntarily participate in and sign the informed consent form;\n2. Gender is not limited;\n3. Age: ≥18 years old and ≤75 years old (stage Ia); ≥18 years old (stage Ib);\n4. Locally advanced or metastatic non-small cell lung cancer and other solid tumors;\n5. Must have at least one measurable lesion that meets the RECIST v1.1 definition;\n6. have archived primary or recurrent tumor tissue specimens that can be submitted for central review;\n7. ECOG ≤1;\n8. The expected survival time as judged by the investigators was ≥3 months;\n9. Bone marrow function, renal function and liver function should meet the requirements;\n10. Coagulation function: fibrinogen ≥1.5g/L; Activated partial thromboplastin time (APTT) ≤1.5×ULN; Prothrombin time (PT) ≤1.5×ULN;\n11. Fertile female subjects or male subjects with fertile partners must use highly effective contraception from 7 days before the first dose until 12 weeks after the last dose. Female subjects of childbearing potential must have a negative serum pregnancy test within 7 days before the first dose;\n12. Subjects were able and willing to comply with protocol-specified visits, treatment plans, laboratory tests, and other study-related procedures.\n\nExclusion Criteria:\n\n1. Chemotherapy, biological therapy, immunotherapy and other anti-tumor therapies have been used within 4 weeks or 5 half-lives before the first dose; Mitomycin and nitrosoureas were administered within 6 weeks before the first dose; Oral drugs such as fluorouracil;\n2. Patients with active infection requiring intravenous antibiotics who did not complete treatment within 1 week before enrollment;\n3. Positive human immunodeficiency virus antibody, active tuberculosis, active hepatitis B virus infection or hepatitis C virus infection;\n4. No reduction in toxicity from previous antineoplastic therapy to grade I as defined in CTCAE, version 5.0, or to the level specified in the inclusion criteria;\n5. Patients at risk for active autoimmune disease or with a history of autoimmune disease may have central nervous system involvement;\n6. Pulmonary disease defined as ≥ grade 3 according to NCI-CTCAE v5.0; A history of ILD requiring steroid therapy, or current ILD or grade ≥2 radiation pneumonitis;\n7. Patients with previous allogeneic hematopoietic stem cell transplantation or organ transplantation;\n8. Had a history of severe cardiovascular and cerebrovascular diseases;\n9. Patients had or had thrombotic events such as deep vein thrombosis, arterial thrombosis and pulmonary embolism within 6 months before screening;\n10. Brain parenchymal metastases and/or meningeal metastases or spinal cord compression, excluding stable and asymptomatic brain parenchymal metastases;\n11. Uncontrolled pleural effusion with clinical symptoms who were judged by the investigator to be ineligible for enrollment;\n12. Poorly controlled hypertension (systolic blood pressure \\> 150 mmHg or diastolic blood pressure \\> 100 mmHg);\n13. Who had participated in a clinical trial of an unmarketed drug within 4 weeks before the trial dose;\n14. Had received a live vaccine within 4 weeks before the trial dose;\n15. Other circumstances that the investigator deemed inappropriate for participation in the trial."}, "identificationModule"=>{"nctId"=>"NCT06612840", "briefTitle"=>"A Study of GNC-077 in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer and Other Solid Tumors", "organization"=>{"class"=>"INDUSTRY", "fullName"=>"Sichuan Baili Pharmaceutical Co., Ltd."}, "officialTitle"=>"An Open-label, Multicenter, Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics Characteristics or Preliminary Efficacy and Antitumor Activity of GNC-077 Multi-specific Antibody Injection in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Other Solid Tumors", "orgStudyIdInfo"=>{"id"=>"GNC-077-101"}}, "armsInterventionsModule"=>{"armGroups"=>[{"type"=>"EXPERIMENTAL", "label"=>"GNC-077", "description"=>"Participants receive GNC-077 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.", "interventionNames"=>["Drug: GNC-077"]}], "interventions"=>[{"name"=>"GNC-077", "type"=>"DRUG", "description"=>"Administration by intravenous infusion for a cycle of 3 weeks.", "armGroupLabels"=>["GNC-077"]}]}, "contactsLocationsModule"=>{"locations"=>[{"city"=>"Shanghai", "state"=>"Shanghai", "country"=>"China", "contacts"=>[{"name"=>"Caicun Zhou", "role"=>"CONTACT"}], "facility"=>"Shanghai East Hospital", "geoPoint"=>{"lat"=>31.22222, "lon"=>121.45806}}], "centralContacts"=>[{"name"=>"Sa Xiao, PHD", "role"=>"CONTACT", "email"=>"xiaosa@baili-pharm.com", "phone"=>"15013238943"}], "overallOfficials"=>[{"name"=>"Caicun Zhou, PHD", "role"=>"PRINCIPAL_INVESTIGATOR", "affiliation"=>"Shanghai East Hospital"}]}, "sponsorCollaboratorsModule"=>{"leadSponsor"=>{"name"=>"Sichuan Baili Pharmaceutical Co., Ltd.", "class"=>"INDUSTRY"}, "collaborators"=>[{"name"=>"Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.", "class"=>"INDUSTRY"}], "responsibleParty"=>{"type"=>"SPONSOR"}}}}